Short answer
Biomarin Pharmaceutical Inc (BMRN) filed an 8-K current report with the SEC on February 23, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q4 2025 earnings announced Feb 23, 2026: full results in Exhibit 99.1 press release.
Biomarin Pharmaceutical Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4 2025 earnings announced Feb 23, 2026: full results in Exhibit 99.1 press release
- Filing covers fiscal quarter ended December 31, 2025
- Furnished (not filed) under SEC rules: limits legal liability but reduces investor protections under Exchange Act
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Biomarin Pharmaceutical Inc 8-K filings
Get the next BMRN 8-K as it lands
Follow BMRN for push alerts, or ask the research agent what this filing means.